Furthermore, another study showed that nivolumab was not significantly associated with increased PFS (4.2 vs. 5.9 months) compared to chemotherapy in patients with previously untreated stage IV or recurrent NSCLC with 5% or more PD-L1 expression. Here, CD274 is linked to non-small cell lung carcinoma.